We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0QGW market cap is 1.48B. The company's latest EPS is PLN 1.4351 and P/E is 63.69.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| PLN (PLN) | PLN (PLN) | PLN (PLN) | PLN (PLN) | PLN (PLN) | |
| Total Revenue | 0 | 0 | 0 | 56.87M | 163.98M |
| Operating Income | -64.08M | -62.94M | -54.65M | -6.93M | 28.1M |
| Net Income | -68.87M | -63.74M | -55.77M | 1.9M | 23.19M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| PLN (PLN) | PLN (PLN) | PLN (PLN) | PLN (PLN) | PLN (PLN) | |
| Total Assets | 144.72M | 113.55M | 78.32M | 184.24M | 186.18M |
| Total Liabilities | 102.58M | 135.13M | 155.71M | 130.92M | 109.67M |
| Total Equity | 42.14M | -21.58M | -77.39M | 53.31M | 76.51M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| PLN (PLN) | PLN (PLN) | PLN (PLN) | PLN (PLN) | PLN (PLN) | |
| Operating | -38.94M | -33.76M | -35.24M | -32.91M | 38.84M |
| Investing | -6.77M | -9.16M | -3.01M | -31.28M | -16.06M |
| Financing | 103.09M | 12.47M | 12.67M | 110.51M | -17.84M |
| Market Cap | 1.48B |
| Price to Earnings Ratio | 63.69 |
| Price to Sales Ratio | 9.01 |
| Price to Cash Ratio | 27.54 |
| Price to Book Ratio | 19.31 |
| Dividend Yield | - |
| Shares Outstanding | 16.16M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Mabion Sa |
| Address |
ul. gen. mariana langiewicza 60 lodz 95-050 |
| Website | https://www.mabion.eu |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
